Osteoporosis marketopportunitiesCairoPrepared by: Walid Saafan
Topics Summary Market Overview Medical analysis Promotional analysis Cost analysis for leading brands
SummaryThe Osteoporosis market size:  – Sales: 10.2 Mio US$ in representing 0.4% of the total market GR%    +9.9%, and CAG...
Summary – cont., The MKT is consisting of 3 trends  – Bisphosphonate: divided to Alendronate group mainly Fosavance/    Fo...
Market overview – leading classesMarket segmentation                                Source: IMS Y09, values in US$
Market overview – leading classes cont.,Leading corporate per class   Leading brands per class                            ...
Market overview – market developmentTotal pharma.                +19.5%   +19.7%   +18.9%            +16.4%Market GR%     ...
Market overview – Leading corporate performance                               Source: IMS Y09, values in US$
Market overview – Leading brands performance                               Source: IMS Y09, values in US$
Medical analysis - Source of RXs The osteoporosis Rx are mainly generated from ORTH doctors contributing with 75% of all a...
Medical analysis - Source of RXsLeading brands per specialty   Leading brand source of RXs                                ...
Promotional analysis - Target specialties ORTHO is the main target for details acquiring 68% of the total details. New shi...
Promotional analysis - Leading corp. targetingLeading corporate per class   Corporate target classes                      ...
Promotional analysis - Share of voice - ORTHO Novartis has the highest SoV among ORTHO of 25% (Miacalcic 16% with GR% +41%...
Promotional analysis - Detail SoV analysisLeading brands per specialty   Brand target classes                             ...
Cost analysis for main brands                                Source: IMS, Prices in EGP
Thank you
Leading brands per class                        Sales US$  CAGR    GR%Osteop.MKT.             10,207,855 10.7       9.9M05...
Leading specialties – RXs                     Y09 Projected RXs                          Total Others          GYN, 18,075...
SOT               PSP Osteoprosis market  MIACALCIC                   17               316  PROTELOS                    23...
Chart Title                  450                                                                   MIACALCIC              ...
Upcoming SlideShare
Loading in...5
×

EGYPT Osteoporosis market analysis 2010

848

Published on

Osteoporosis market opportunities.
Egypt 2010

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
848
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
31
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

EGYPT Osteoporosis market analysis 2010

  1. 1. Osteoporosis marketopportunitiesCairoPrepared by: Walid Saafan
  2. 2. Topics Summary Market Overview Medical analysis Promotional analysis Cost analysis for leading brands
  3. 3. SummaryThe Osteoporosis market size: – Sales: 10.2 Mio US$ in representing 0.4% of the total market GR% +9.9%, and CAGR 10.7% vs total market GR% of +16.4% and CAGR +18.3%. – Units: 559K packs, GR% +10.4% and CAGR +7.4% vs total market GR% +11.7% and CAGR +9.7%.Osteoporosis market is derived by Multinational corporations(Novartis, MSD, Servier, and Sanofi Aventis) represent 85% of themarket.The osteoporosis is not reimbursed in the MOH and the sales aredriven from the private market (out pocket).The market is derived by Bisphosphonate class representing 54% ofthe total market followed be Calcitonins representing 32%, bothclasses represent 86% of the market. Source: IMS Y09
  4. 4. Summary – cont., The MKT is consisting of 3 trends – Bisphosphonate: divided to Alendronate group mainly Fosavance/ Fosamax from MSD with 8 generics, Residronate group mainly Actonel from Sanofie Aventis with two generic. – Calcitonin: the oldest trend led by Miacalcic launched in 1986 – Raloxifen: leading the group Evista from Lilly with 4 generics. The main segment prescribing antiresorptive for osteoporosis are the ORTH with 76% Rx share and GR of +11%. Source: IMS Y09
  5. 5. Market overview – leading classesMarket segmentation Source: IMS Y09, values in US$
  6. 6. Market overview – leading classes cont.,Leading corporate per class Leading brands per class Source: IMS Y09, values in US$
  7. 7. Market overview – market developmentTotal pharma. +19.5% +19.7% +18.9% +16.4%Market GR% Source: IMS Y09, values in K.US$
  8. 8. Market overview – Leading corporate performance Source: IMS Y09, values in US$
  9. 9. Market overview – Leading brands performance Source: IMS Y09, values in US$
  10. 10. Medical analysis - Source of RXs The osteoporosis Rx are mainly generated from ORTH doctors contributing with 75% of all antiresorptive Rx. Other specialties show minor contribution with a growing potential for the GP segment. The market is showing low level of stay on therapy for most of brands with an average of 1.8 Pack/Rx for Miacalcic, 1.6 for Protelos and 2 for Actonel and Fosavance. Source: IMS MAT Q4/09
  11. 11. Medical analysis - Source of RXsLeading brands per specialty Leading brand source of RXs Source: IMS MAT Q4/09
  12. 12. Promotional analysis - Target specialties ORTHO is the main target for details acquiring 68% of the total details. New shift from ORTHO towards IM in Y09. Source: IMS MAT Q4/09
  13. 13. Promotional analysis - Leading corp. targetingLeading corporate per class Corporate target classes Source: IMS MAT Q4/09
  14. 14. Promotional analysis - Share of voice - ORTHO Novartis has the highest SoV among ORTHO of 25% (Miacalcic 16% with GR% +41%& ACLASTA +9% with GR% +22%) with increased focus on IM. PROTELOS has the highest SoV of 22% with GR% +29% Source: IMS MAT Q4/09
  15. 15. Promotional analysis - Detail SoV analysisLeading brands per specialty Brand target classes Source: IMS MAT Q4/09
  16. 16. Cost analysis for main brands Source: IMS, Prices in EGP
  17. 17. Thank you
  18. 18. Leading brands per class Sales US$ CAGR GR%Osteop.MKT. 10,207,855 10.7 9.9M05B3 BISPHOSPH 5,498,920 9.9 10.6 FOSAVANCE/FOSAMAX 1,884,977 1.9 (0.3) ACTONEL 1,229,611 -6.9 (11.6) ACLASTA 1,139,665 --- 72.4H04A0 CALCITONINS 3,224,716 4.6 7.2 MIACALCIC/PLUS 3,170,595 4.1 10.6M05B9 CALCIUM REGULAT 1,341,167 88.6 20.3 PROTELOS 1,293,199 107.7 21.0G03J0 SERMS 109,414 -30 (34.1)
  19. 19. Leading specialties – RXs Y09 Projected RXs Total Others GYN, 18,075, (6) , 14,390, 6% 5% G.P., 39,939, 13% ORTHO., 237,080, 76%
  20. 20. SOT PSP Osteoprosis market MIACALCIC 17 316 PROTELOS 23 124 ACTONEL 26 107 ACLASTA 64 1,860 FOZAMAX/FOSAVANCE 31 100 Monthly Yearly Treatment treatment cost cost Leading brands MIACALCIC 367 4,405 PROTELOS 269 3,233 ACTONEL 233 2,802 ACLASTA 1,860 FOZAMAX/FOSAVANCE 217 2,607NB: brand prices calculated based on the weighted average of its SKU’s publicsales price times the units sales
  21. 21. Chart Title 450 MIACALCIC 400 PROTELOS 350 ACTONEL 300Price per month 250 200 150 100 50 - - 10 20 30 40 50 60 70 80 Stay on therapy
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×